Biosimilars have the potential to be considered comparable to generics and offer healthcare benefits...
Read moreInternational Reference Pricing (IRP) is a means to control national prices by using prices in other...
Read moreThe latest policy document for the European Commission outlines multiple scenarios for HTA harmonisa...
Read moreThe German Ministry of Health has recently published its final bill concerning changes to the market...
Read moreEnabling physicians to identify patients who are most likely to respond to treatment thereby achievi...
Read moreOver the next two years changes to the marketing authorisation or pricing and reimbursement procedur...
Read moreHow to obtain non-reimbursed prices within the EU was presented at ISPOR's 21st annual international...
Read moreTopics include our perspectives on an EU commission report on how international reference pricing ca...
Read moreWhether ICER will become an integral part of the US healthcare landscape in the future remains to be...
Read moreThis report highlights some "quick wins" that member states can quickly and easily adopt to decrease...
Read more